[Interleukin-2 in the treatment of malignant melanoma. A case report].
Interleukin-2 is a lymphokine with documented antineoplastic influence, with not completely understood mechanism of action. The case of 46-years old patient with relapsed metastatic malignant melanoma treated with constant-infusion of rIL-2 is described. 9-month remission was achieved. During the course of treatment a lot of side effects including flu-like symptoms, hypotonia, anemia and thrombocytopenia, and also many biochemical disturbances were observed.
Szczylik
C
C
Zakładu Immunologii CSK WAM.
Knap
J
J
Badowski
A
A
Ratajczak
M Z
MZ
Siekierzyński
M
M
D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000556:secondary / Q000628:therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D007376:Interleukin-2
Interleukin-2 (IL-2) w leczeniu czerniaka złośliwego. Opis przypadku.